A recombinant protein and a chemically synthesized peptide containing the active peptides of the platelet collagen receptors inhibit ferric chloride-induced thrombosis in a rat model

• Published in: Thrombosis research Vol. 121; no. 3; pp. 419 - 426
• Main Authors: Du, Haiming, Zawaski, Janice A, Gaber, M. Waleed, Chiang, Thomas M
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Ltd 2007; Elsevier Science
• Subjects: Animal model; Animals; Base Sequence; Biological and medical sciences; Blood and lymphatic vessels; Cardiology. Vascular system; Chlorides; Collagen; Collagen Type I - pharmacology; Collagen Type III - pharmacology; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; DNA Primers - genetics; Endocrinopathies; Ferric Compounds - toxicity; Hematology, Oncology and Palliative Medicine; Humans; In Vitro Techniques; Male; Medical sciences; Non tumoral diseases. Target tissue resistance. Benign neoplasms; Peptides - chemical synthesis; Peptides - pharmacology; Platelet; Platelet Adhesiveness - drug effects; Platelet Aggregation - drug effects; Platelet aggregation inhibitor; Platelet Aggregation Inhibitors - chemical synthesis; Platelet Aggregation Inhibitors - chemistry; Platelet Aggregation Inhibitors - pharmacology; Platelet collagen receptor; Rats; Rats, Sprague-Dawley; Receptors, Collagen - chemistry; Receptors, Collagen - genetics; Recombinant Proteins - chemistry; Recombinant Proteins - genetics; Recombinant Proteins - pharmacology; Thrombosis; Thrombosis - blood; Thrombosis - chemically induced; Thrombosis - prevention & control; Thyroid. Thyroid axis (diseases); Platelet collagen receptor; Platelet aggregation inhibitor; Animal model; Platelet; Thrombosis; Collagen; Rat; Glycoprotein; Rodentia; Cardiovascular disease; Vascular disease; Aggregation; Vertebrata; Mammalia; Animal; Recombinant protein
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/j.thromres.2007.05.001

Abstract We have previously reported that a recombinant protein (Mr 47 kDa), which contains both active peptide of platelet receptors for types I and III collagen inhibits both types I and III collagen-induced platelet aggregation. In order to eliminate non-reactive portion of the protein, we have constructed a recombinant of rHyB (Mr 6 kDa). In addition, we chemically synthesized a hybrid peptide with 30 amino acid residues (cHyB, Mr 3 kDa) that contains each of the active peptide derived from platelet receptors for types I and III collagen and a linker of 12 amino acid residues. In the present investigation, we report that both rHyB and cHyB inhibit type I and type III collagen-induced platelet aggregation, and the adhesion of radiolabeled platelets onto rabbit aortic segments in a dose-dependent manner. We have used an animal model, which employs FeCl3 to induce thrombi formation to study the effectiveness of both rHyb and cHyB on preventing thrombi formation. We obtained results that show that both rHyB and cHyB can inhibit thrombi formation in a dose-dependent manner. These results suggest that either rHyB or cHyB may be a possible therapeutic agent in preventing thrombi formation.